AstraZeneca CEO discusses oral weight loss drug agreement with Eccogene

AstraZeneca CEO Soriot on Pharmaceuticals in ChinaПодробнее

AstraZeneca is moving quickly with Covid antibody drug, CEO saysПодробнее

AstraZeneca CEO says manufacturing Covid-19 vaccine is a 'huge undertaking'Подробнее

AstraZeneca CEO says they've reduced emissions by 60%Подробнее

AstraZeneca Supports Trump's Drug-Rebate Overhaul, CEO SaysПодробнее

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateauПодробнее

Pharma industry has a trust issue, AstraZeneca CEO says | CNBC ConversationПодробнее

AstraZeneca enters weight-loss market with oral GLP-1 drugПодробнее

Lose Weight with Maple Syrup. New Research Demonstrates it.Подробнее

GLP-1 drugs: transforming weight loss and Life & Health insuranceПодробнее

Pascal Soriot, CEO, AstraZenecaПодробнее

AstraZeneca 'within striking distance' of curing some cancers, CEO says | CNBC ConversationПодробнее

What Embattled AstraZeneca Should Look For In A New CEOПодробнее

AstraZeneca CEO on Impact of Midterms on Drug MarketПодробнее

AstraZeneca CEO: Objective is to replace chemotherapyПодробнее

AstraZeneca CEO talks blowout earnings, global growth, new drugs, and pricingПодробнее

CEO Pascal Soriot reflects on AstraZeneca's H1 2019 ResultsПодробнее

AstraZeneca CEO receives knighthoodПодробнее

AstraZeneca CEO: “Covid Is Here To Stay”Подробнее